ad-ccl21-dc exd
Vaccineexperimental
Clinical trial activity
1 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2018 (NCT03546361)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03546361 | Phase 1 | Sep 1, 2018 | California Institute for Regenerative Medicine (CIRM), LUNGevity Foundation, Merck, National Cancer Institute (NCI), University of California, Los Angeles |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| California Institute for Regenerative Medicine (CIRM) | Academic/Hospital | 1 | 0 | 1 | 2018 |
| LUNGevity Foundation | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Merck | For profit | 1 | 0 | 1 | 2018 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2018 |
| University of California, Los Angeles | Academic/Hospital | 1 | 1 | 1 | 2018 |
5 organizations
Page 1 / 1